Cantor Fitzgerald Predicts ARTV FY2024 Earnings

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) – Analysts at Cantor Fitzgerald issued their FY2024 earnings estimates for Artiva Biotherapeutics in a research report issued to clients and investors on Wednesday, November 13th. Cantor Fitzgerald analyst J. Schimmer expects that the company will earn ($3.63) per share for the year. Cantor Fitzgerald has a “Overweight” rating and a $23.00 price objective on the stock. The consensus estimate for Artiva Biotherapeutics’ current full-year earnings is ($4.49) per share.

ARTV has been the subject of a number of other reports. Wedbush restated an “outperform” rating and set a $18.00 price target on shares of Artiva Biotherapeutics in a report on Friday, August 30th. TD Cowen started coverage on Artiva Biotherapeutics in a research note on Tuesday, August 13th. They set a “buy” rating for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 price target on shares of Artiva Biotherapeutics in a research report on Wednesday, November 13th. Finally, Jefferies Financial Group initiated coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued a “buy” rating and a $21.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $21.25.

Artiva Biotherapeutics Stock Up 2.5 %

NASDAQ ARTV opened at $10.31 on Monday. Artiva Biotherapeutics has a 1 year low of $9.68 and a 1 year high of $17.31. The business’s fifty day moving average price is $12.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24).

Institutional Trading of Artiva Biotherapeutics

Hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics during the third quarter valued at approximately $42,000. MetLife Investment Management LLC acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $135,000. Barclays PLC acquired a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $304,000. Charles Schwab Investment Management Inc. bought a new stake in Artiva Biotherapeutics in the third quarter valued at $623,000. Finally, Acuta Capital Partners LLC acquired a new position in Artiva Biotherapeutics during the third quarter worth $680,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.